JAK3 and T-cell large granular lymphocyte leukemia: Tofacitinib citrate, a JAK3-specific inhibitor, showed good response in patients with refractory LGLL associated with RA (30); furthermore, BNZ-1, a multicytokine inhibitor, is currently being tested in LGLL patients in a phase I/II trial (57).